IAG Announce the Acceptance of 2 Abstracts from Clinical Studies in Rheumatoid and Juvenile Rheumatoid Arthritis at EULAR 2017
IAG, Image Analysis Group announces the acceptance of two abstracts from clinical studies in Rheumatoid and Juvenile Rheumatoid Arthritis by the Annual European Congress of Rheumatology organized by the European League Against Rheumatism (EULAR) 2017, held in Madrid from 14-17 June.
Pre and post treatment MRI of a patient with rheumatoid arthritis processed with DYNAMIKA. In colour: map of maximum enhancement showing the most active areas of synovial inflammation in yellow-white and less active – red. Quantitative comparison of the volume and level of inflammation is shown in the bottom left corner. The graphs correspond to the time intensity vs synovial enhancement in the MCP joint selected in the pre and post treatment images.
Following is a list of accepted abstracts:
“Quantification of Dynamic MRI Examinations in Juvenile Idiopathic Arthritis,” N. Tzaribachev, R. Hagoug, P. Louka, J. Islam, M. Hinton, O. Kubassova, M. Boesen, showing that in 18 patients statistically significant and clinically meaningful changes were documented for Dynamic Contrast Enhanced MR Quantification (DEMRIQ) method. In all patients sub-clinical disease could be detected on MRI in clinically unaffected joints. The abstract will be presented as a poster on 17 June 2017 at 10:15 Poster area / Poster session III.
“Dynamic Contrast Enhanced MRI in Randomised Placebo-Controlled Rheumatoid Arthritis Trial – Impact of Applying Joint Coverage Quality Criteria,” M. B. Axelsen, H. Bliddal, L. T. H. Jacobssen, M. S. Hansen, A. Dudek, M. Rell-Bakalarska, M. Boesen, J. Stefanek, B. Sundman-Engberg, M. Østergaard emphasises the importance of standartization of DCE-MRI as an critical imaging endpoint in efficacy trials
The European League Against Rheumatism (EULAR) is the organization which represents the patient, health professional and scientific societies of rheumatology of all the European nations. EULAR endeavors to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. In line with UEMS, EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com